Fendler, Wolfgang P.
Calais, Jeremie
Eiber, Matthias
Simko, Jeffrey P.
Kurhanewicz, John
Santos, Romelyn Delos
Feng, Felix Y.
Reiter, Robert E.
Rettig, Matthew B.
Nickols, Nicholas G.
Kishan, Amar U.
Shozo, Okamoto
Emmett, Louise
Zacho, Helle D.
Ilhan, Harun
Rischpler, Christoph
Wetter, Axel
Schoder, Heiko
Burger, Irene A.
Slavik, Roger
Carroll, Peter R.
Lawhn-Heath, Courtney
Herrmann, Ken
Czernin, Johannes
Hope, Thomas A.
,
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 3 April 2020
Accepted: 28 June 2020
First Online: 17 August 2020
Compliance with ethical standards
:
: Wolfgang P. Fendler was a consultant for Ipsen, Endocyte, and BTG, and he received personal fees from RadioMedix outside of the submitted work. Jeremie Calais reports consulting activities for Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, Progenics Pharmaceuticals, Radiomedix, and Telix Pharmaceuticals outside of the submitted work. Matthias Eiber is consultant for ABX and Blue Earth Diagnostics. Johannes Czernin is a founder, board member, and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. Johannes Czernin serves on the medical advisory board of Actinium and is a member of the VISION trial steering committee, a clinical trial sponsored by Endocyte. Thomas Hope is a consultant for GE Healthcare and Ipsen and receives grant support from GE Healthcare. Matthew Rettig is speaker and advisory board member for Janssen and receives research funding from Novartis. No other potential conflicts of interest relevant to this article have been disclosed.
: The prospective trial was approved by ethics committees at UCLA and UCSF.
: All patients signed written informed consent.
: All patients gave written consent.